Sagar Lonial, MD, FACP, summarizes a case concerning a 78-year-old man with multiple myeloma, including initial impressions and prognosis at diagnosis.
A 78-Year-Old Man With Multiple Myeloma
Sagar Lonial, MD, FACP, highlights first-line therapies available for transplant-ineligible newly diagnosed multiple myeloma, with special considerations regarding comorbidities.
Sagar Lonial, MD, FACP, discusses the efficacy data from the phase 3 MAIA study, as well as the role of daratumumab when treating newly diagnosed patients with multiple myeloma.
Sagar Lonial, MD, FACP, explains the importance of daratumumab/lenalidomide/low-dose dexamethasone (DRd) in several key areas, including progression-free survival versus common standard-of-care regimens in the PEGASUS trial, toxicities, and how active patients fare.
Sagar Lonial, MD, FACP, focuses on the treatment of multiple myeloma during the COVID-19 pandemic, discussing the standard of care with anti-CD38 monoclonal antibodies and daratumumab.
Sagar Lonial, MD, FACP, summarizes current challenges and his hopes for the future concerning the treatment of multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5